| Clinical features analysis of Castleman disease patients |
| Received:August 03, 2021 Revised:November 19, 2021 Click here to download the full text |
| Citation of this paper:GU Shi-yang,WEI Zheng,JI Li-li,WANG Zhi-mei,ZHUANG Jing-li,CHENG Zhi-xiang,WANG Wei-guang,YUAN Ling,CHENG Lu-ya,KE Yang,LIU Peng.Clinical features analysis of Castleman disease patients[J].Chinese Journal of Clinical Medicine,2022,29(4):610-614 |
| Hits: 744 |
| Download times: 318 |
| Author Name | Affiliation | E-mail | | GU Shi-yang | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | WEI Zheng | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | JI Li-li | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | WANG Zhi-mei | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | ZHUANG Jing-li | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | CHENG Zhi-xiang | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | WANG Wei-guang | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | YUAN Ling | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | CHENG Lu-ya | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | KE Yang | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | LIU Peng | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | liu.peng@zs-hospital.sh.cn |
|
| Abstract:Objective To analyze clinical pathological and therapeutic features of Castleman disease (CD). Methods Totally, 95 patients were enrolled and their clinical features, lablatory results, pathological features, treatment and survival data were collected. Results Among the CD patients, hyaline vascular pathological subtype accounted for 58.9% (56/95); Uni-center CD (UCD) accounted for 72.6% (69/95) while muitl-center CD (MCD) accounted for 27.4% (26/95). Twenty-one patients had idiopathic MCD-not otherwise specified (iMCD-NOS) subtype. There were significant differences in the pathological subtype, maximum diameter of lesions, the ratios of B symptoms, splenomegaly, and serous effusion, and several laboratory factors between UCD and MCD subgroup (P<0.05). Laboratory examination showed lymphocytopenia happened in 39(41.1%) patients.UCD and asymptomatic MCD (aMCD) patients were free from systemic medication,while iMCD patients were undertaken systemic medication including glucocorticoid, immunomodulatory drugs, rituximab and/or chemotherapy. For all the patients, estimated 3-year progression-free survival (PFS) and overall survival (OS) rates were 78.8% and 92.2%; While for MCD subgroup, estimated 3-year OS and 5-year OS rates were 78.2% and 70.2%. Conclusions The proportions of splenomegaly and serous effusion are low in CD patients, while the lymphocytes decreases, and estimated 5-year OS rate in MCD patients is better than previously reports. |
| keywords:Castleman disease idiopathic MCD-not otherwise specified subtype lymphocytopenia therapy survival rate |
| HTML View Full Text View/Add Comment Download reader |
|
|
|